The acquisition allows VBI to develop its own VLP-based vaccines by leveraging its suite of thermostable vaccine formulation technologies.
The terms of the deal were not disclosed.
VBI president and CEO Jeff Baxter said the acquisition enables VBI to strategically build upon their pipeline of vaccine delivery technologies and advance the development of an extremely promising VLP platform.